Articles tagged "Heart transplant patients"

2018 American Transplant Congress
Impact of Infections on Patients with Left Ventricle Assist Devices(LVAD): Allo-Sensitization and Heart Transplantation
C. Buto-Colletti, P. Kimball, K. Shah, M. Quader.
Virginia Commonwealth University, Richmond.
Background: The impact of post-LVAD infections on allosensitization and heart transplantation (HT) is unknown. High levels of panel reactive antibodies (PRA) preclude HT but the…
2018 American Transplant Congress
Long-Term Success of Treatment for Cardiac Transplant AMR May Depend Upon Suppressing Class II Donor Specific Antibodies
J. Hofmann,¹ D. Weisshaar,² D. Kiprov.³
¹Dept of Medicine, California Pacific Medical Center, San Francisco, CA; ²Dept of Medicine, Kaiser Permanente, Santa Clara, CA.
Antibody mediated rejection (AMR) in cardiac transplant (tspt) patients (pts) is primarily mediated by donor specific antibodies (DSAs) and associated with reduced long-term graft survival.…
2018 American Transplant Congress
Risk of Infection in Treatment of Acute Cellular Rejection in Heart Transplant Recipients
T. Fallah, A. Logan, A. Rumore, C. Doligalski.
Tampa General Hospital, Tampa, FL; University of North Carolina, Chapel Hill, NC.
There has been no publication of the incidence of infection (infxn) after the treatment of acute cellular rejection (ACR) in heart transplant recipients (HTR). We…
2018 American Transplant Congress
The Utility of a CD31/CD68 Dual Immunohistochemical Stain to Improve Accurate Diagnosis of Antibody Mediated Rejection in Cardiac Transplantation
C. Glass, Y. Butt, T. Gokaslan, J. Torrealba.
Thoracic Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
Antibody mediated rejection (AMR) occurs in 10%-20% of cardiac transplant patients and is associated with increased mortality. The endomyocardial biopsy, used to identify microvascular injury…
2018 American Transplant Congress
The Overriding Importance of HLA-DR Donor-Specific Antibody That is Correlated to CAV after Heart Transplant
E. Kransdorf, J. Patel, M. Kittleson, S. Dimbil, R. Levine, D. Geft, D. Chang, L. Czer, J. Kobashigawa.
Cedars Sinai Medical Center, Los Angeles.
Purpose: Class II donor specific anti-HLA antibodies (DSA) have been correlated to subsequent CAV development. More specifically, HLA-DQ has been most reported for CAV development.…
2018 American Transplant Congress
Decreased Post Heart Transplant Survival with Epstein-Barr Virus Mismatch in the Current Era
M. Kittleson, J. Patel, E. Kransdorf, S. Dimbil, R. Levine, S. Mersola, D. Geft, D. Chang, L. Czer, J. Kobashigawa.
Cedars Sinai Medical Center, Los Angeles.
Purpose: Epstein-Barr virus (EBV) has been implicated in a multitude of cancers, including B-cell lymphoma, Burkitt's lymphoma, CNS lymphoma, gastric cancer and nasopharyngeal carcinoma. Previous…
2018 American Transplant Congress
Elevated Serum Penteraxin in Cardiac Allograft Antibody Mediated Rejection: From Cytokine Arrays to Patients with ABMR
O. Moussa,³ M. Kavarana,² L. Klingman,¹ J. Felius,¹ S. Hall,¹ M. Askar.¹
¹Baylor Research Institute, Dallas; ²Medical University of South Carolina, Charleston; ³University of Michigan, Ann Arbor, MI.
Pentraxin 3 (PTX3) is soluble protein that has been implicated in in atherosclerosis, endothelial function, hypertension, myocardial infarction and angiogenesis (Fornai et al., 2016). We…
2018 American Transplant Congress
Urinary Cell Cycle Arrest Biomarkers as Early Predictors of Acute Kidney Injury Following Advanced Cardiac Replacement Therapies
S. Joseph, H. Medel-Martinez, T. Bottiglieri, B. Wasek, S. Yeramaneni, J. Felius, C. Bonilla, O. Sido, C. Gottlich, B. Lima, S. Hall.
Baylor University Medical Center, Dallas, TX.
Background: Current strategies to detect acute kidney injury (AKI) after cardiothoracic surgery rely on elevations in serum creatinine and diminished urine output, which are insensitive…
2018 American Transplant Congress
Early Adjunctive Treatment with Human Cytomegaly Virus (CMV) Immunoglobulin Increased CMV-Free Survival after Heart Transplantation
M. Barten,¹ C. Neumaier,¹ A. Bernhardt,¹ M. Rybczynski,² R. Plaetke,³ H. Reichenspurner.¹
¹Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; ²General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany; ³Institute of Medical Biometry and Epidemiology, University Hospital Eppendorf Hamburg, Hamburg, Germany.
Purpose: There is still an ongoing discussion whether a prophylactic or a preemptive therapy against cytomegalovirus (CMV) is superior to reduce the incidence of CMV…
2018 American Transplant Congress
High Frequency of HLA-DQ De Novo Donor Specific Antibodies is Independent of the Number of Mismatches in Heart Transplant
X. Zhang,¹ E. Kransdorf,² J. Patel,² J. Kobashigawa.²
¹HLA and Immunogenetics Laboratory/ Comprehensive Transplant Center, Cedars-Sinai Health Systems, Los Angeles, CA; ²Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA.
Aim: Development of de novo donor specific antibodies (DSA) after heart transplant is associated with an increased risk of allograft failure. The aim of this…